EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Combination antithymocyte globulin and soluble TNF alpha inhibitor (etanercept) +/- mycophenolate mofetil for treatment of steroid refractory acute graft-versus-host disease



Combination antithymocyte globulin and soluble TNF alpha inhibitor (etanercept) +/- mycophenolate mofetil for treatment of steroid refractory acute graft-versus-host disease



Bone Marrow Transplantation 37(12): 1143-1147



Antitumor necrosis factor-alpha antibodies are increasingly being used for the treatment of steroid-refractory acute graft-versus-host disease (GVHD) complicating allogeneic stem cell transplantation. We retrospectively reviewed the outcomes of 16 patients with refractory acute predominantly visceral GVHD treated with combination antithymocyte globulin (ATG), tacrolimus and etanercept +/- mycophenolate mofetil (MMF) at our institution.

(PDF emailed within 1 workday: $29.90)

Accession: 011874204

Download citation: RISBibTeXText



Related references

Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease. Annals of Hematology 84(10): 681-685, 2005

Mycophenolate mofetil for treatment of steroid-refractory acute graft-versus-host disease after pediatric hematopoietic stem cell transplantation. Pediatric Transplantation 19(6): 652-658, 2016

Mycophenolate mofetil is effective only for involved skin in the treatment for steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Annals of Hematology: -, 2016

Mycophenolate mofetil as salvage treatment for steroid-refractory chronic graft versus-host disease in children. Blood 98(11 Part 1): 398a, November 16, 2001

Revisiting mycophenolate mofetil for steroid-refractory acute graft-versus-host disease: Is higher dosing effective in children?. Pediatric Transplantation 19(6): 582-583, 2016

Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biology of Blood and Marrow Transplantation 8(3): 155-160, 2002

Combination Therapy with Inolimomab and Etanercept for Severe Steroid-Refractory Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation 22(1): 179-182, 2016

Mycophenolate mofetil is effective and well tolerated in the treatment of refractory acute and chronic graft-versus-host disease. International Journal of Hematology 83(1): 80-85, 2006

Treatment of steroid-resistant acute graft-versus-host disease with rabbit antithymocyte globulin. Journal of HematoTherapy & Stem Cell Research 9(3): 367-374, 2000

Low-dose antithymocyte globulin for treatment of steroid-pulse-resistant acute graft-versus-host disease. International Journal of Hematology 77(1): 99-102, 2003

Mycophenolate mofetil as rescue therapy for high-risk steroid-refractory chronic graft versus-host-disease. Pediatric Research 53(4 Part 2): 275A, April, 2003

The use mycophenolate mofetil in the treatment of refractory chronic graft versus host disease. Blood 92(10 SUPPL 1 PART 1-2): 346B, Nov 15, 1998

Antithymocyte globulin therapy for steroid-resistant acute graft versus host disease. American Journal of Hematology 83(10): 824-825, 2008

Antithymocyte globulin in the management of steroid-resistant acute graft-versus-host disease. Clinical & Investigative Medicine 19(4 SUPPL ): S32, 1996

Treatment of acute and chronic graft versus host disease with mycophenolate mofetil. Blood 94(10 SUPPL 1 PART 2): 368b, Nov 15, 1999